Home – new2024-02-21T18:32:29-08:00

The future of
precision medicine
is here.

Founded by Mark McKenna, the former CEO of Prometheus Biosciences, a successful precision immunology company that sold to Merck in 2023, along with the former Prometheus Biosciences executive team they have set out to continue their work to find best in class therapies to treat multiple immune-mediated and fibrotic diseases from a knowledge and experience vantage point we call this the mirador. 

Driven by our deep
expertise and passion.

The Mirador team is leveraging Mirador360™, our proprietary precision medicine engine, to rapidly build a pipeline of therapies to address unmet patient needs in inflammatory and fibrotic diseasesThis coupled with our pipeline programs and business development efforts Mirador Therapeutics endeavors to lead the industry in immunology and inflammation. 

Latest News

Go to Top